Switch to:
More From Other Websites
Leading Sarcoma Expert Dr. Earl W. Brien Joins CytRx Board of Directors Dec 02 2016
CytRx CEO Pockets Millions of Dollars as Failed Sarcoma Drug Moves to FDA Nov 29 2016
CytRx Corp Conference Call to Discuss Results of Phase 3 Trial of Aldoxorubicin scheduled for 8:30... Nov 29 2016
CytRx Reports Statistically Significant Updated Results from Pivotal Phase 3 Trial of Aldoxorubicin... Nov 29 2016
CYTRX CORP Files SEC form 8-K, Regulation FD Disclosure Nov 29 2016
CYTRX CORP Financials Nov 17 2016
CytRx Gets a Second Look (CYTR) Nov 16 2016
Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive Nov 15 2016
CYTRX CORP Files SEC form 8-K, Unregistered Sale of Equity Securities Nov 14 2016
CytRx Presents Positive Interim Results from On-going Phase 1b/2 Aldoxorubicin Combination Clinical... Nov 11 2016
CytRx Presents Positive Interim Results from On-going Phase 1b/2 Aldoxorubicin Combination Clinical... Nov 11 2016
CYTRX CORP Files SEC form 8-K, Results of Operations and Financial Condition Nov 09 2016
CytRx Reports Third Quarter 2016 Financial Results Nov 09 2016
CytRx reports 3Q loss Nov 09 2016
CytRx reports 3Q loss Nov 09 2016
CytRx Reports Third Quarter 2016 Financial Results Nov 09 2016
CYTRX CORP Files SEC form 10-Q, Quarterly Report Nov 09 2016
CYTRX CORP Files SEC form 8-K, Change in Directors or Principal Officers Oct 19 2016
What CytRx Latest Trial Results Really Mean (CYTR) Oct 17 2016
CytRx Presents Interim Results from On-going Aldoxorubicin Plus Ifosfamide/Mesna Combination... Oct 10 2016


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK